Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN

(AMGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Amgen : Biotech Startup Nkarta Therapeutics Raises $114 Million in Series B Financing

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/04/2019 | 12:14pm EDT

By Colin Kellaher

Biotechnology startup Nkarta Therapeutics on Wednesday said it raised $114 million in an oversubscribed Series B funding round at an undisclosed valuation.

Nkarta, which is developing engineered natural killer cell therapies to fight cancer, said new investor Samsara BioCapital led the round.

New investors Amgen Inc.'s (AMGN) Amgen Ventures, Deerfield Management, Life Science Partners, Logos Capital and RA Capital Management also participated, joined by existing investors NEA Ventures, SR One and Novo Holdings A/S, Nkarta said.

The South San Francisco, Calif., company, founded in 2015, said it will use the funding to advance multiple programs into clinical trials.

Nkarta, which previously raised $11 million in a Series A financing, also said it expects to complete a manufacturing facility in South San Francisco next year to supply investigational product for its early-stage clinical trials.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
09/13AMGEN : To Present At The Bank of America Merrill Lynch Global Healthcare Confer..
PR
09/13AMGEN : Investor Insights Newsletter Q2 2019
PU
09/13AMGEN : Phase 3 Study of Kyprolis, Darzalex Meets Primary Endpoint
DJ
09/13AMGEN : Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DAR..
PU
09/12AMGEN : Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline A..
PR
09/10Henlius Biotech launches $477 million HK IPO, testing market amid protests
RE
09/10AMGEN : Joins Single Most Ambitious Whole Genome Sequencing Project Ever Underta..
PU
09/09AMGEN : Comments on ICER's Proposed Methods Adaptations For Assessments of Poten..
PU
09/09AT&T and Acadia post gains while Clorox and Amgen stumble
AQ
09/09Wall Street ends flat amid rate hopes, tech declines
RE
More news
Financials (USD)
Sales 2019 22 821 M
EBIT 2019 10 873 M
Net income 2019 7 734 M
Debt 2019 2 689 M
Yield 2019 2,96%
P/E ratio 2019 15,4x
P/E ratio 2020 14,7x
EV / Sales2019 5,25x
EV / Sales2020 4,93x
Capitalization 117 B
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 217,10  $
Last Close Price 195,47  $
Spread / Highest target 24,3%
Spread / Average Target 11,1%
Spread / Lowest Target -11,5%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline CFO, Chief Accounting Officer & Executive VP
David M. Reese Executive Vice President-Research & Development
Frank C. Herringer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN0.41%117 224
JOHNSON & JOHNSON1.07%345 150
ROCHE HOLDING LTD.10.52%236 116
MERCK AND COMPANY8.11%211 513
PFIZER-15.44%204 151
NOVARTIS18.45%200 777